FDA supplemental approval: Tramadol Hydrochloride (REMS)

AI Summary

The FDA approved a supplemental REMS (Risk Evaluation and Mitigation Strategy) for tramadol hydrochloride extended-release tablets (100 mg, 200 mg, and 300 mg) manufactured by MacLeods Pharms, effective 18 June 2026. This is a regulatory compliance action that establishes required risk management controls; it does not report clinical trial results or comparative efficacy data.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for tramadol hydrochloride extended-release tablets; this is a regulatory action, not a clinical efficacy study.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory record confirms that tramadol hydrochloride extended-release products are subject to REMS requirements to manage risks associated with opioid use. Clinicians and dispensers must comply with REMS provisions when prescribing or dispensing these products; however, this document does not provide information about efficacy, safety trials, or comparative clinical benefit.

Caveats

• This record does not contain clinical trial results, efficacy data, or safety outcomes.
• REMS approval indicates regulatory compliance framework only; it does not imply new clinical evidence or superiority.
• No information on specific REMS requirements, patient population restrictions, or prescriber requirements is provided in this record.
• Dosage strengths and formulations approved are listed, but no clinical dosing recommendations or pharmacokinetic data are reported.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.